Drug Type Small molecule drug |
Synonyms CRLX-101, HG-6, IT-101 |
Target |
Mechanism HIF-1α inhibitors(Hypoxia-inducible factor 1 alpha inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic castration-resistant prostate cancer | Phase 2 | US | 26 Mar 2019 | |
Recurrent Primary Peritoneal Carcinoma | Phase 2 | US | 01 Jul 2015 | |
Metastatic Renal Cell Carcinoma | Phase 2 | US | 01 Jul 2014 | |
Metastatic Renal Cell Carcinoma | Phase 2 | KR | 01 Jul 2014 | |
Extensive stage Small Cell Lung Cancer | Phase 2 | US | 16 Jan 2013 | |
Small cell lung cancer recurrent | Phase 2 | US | 16 Jan 2013 | |
Adenocarcinoma of Esophagus | Phase 2 | US | 01 Nov 2012 | |
Advanced Gastric Adenocarcinoma | Phase 2 | US | 01 Nov 2012 | |
Esophageal Squamous Cell Carcinoma | Phase 2 | US | 01 Nov 2012 | |
Gastroesophageal junction adenocarcinoma | Phase 2 | US | 01 Nov 2012 |
Phase 2 | 4 | fkbhyusjpx(wfrrwpceqz) = watjyqtoov pmekxeueuk (dsnfutkyuq, hblpyeachh - sgfutcikyi) View more | - | 12 Jul 2022 | |||
NCT01652079 (Pubmed) Manual | Phase 2 | 63 | bhppfhyxmt(zdqcgpmtcj) = jiliojgzmc lpmsaekntm (spbyfoxour ) View more | Positive | 01 Sep 2021 | ||
bevacizumab+CRLX101 | bhppfhyxmt(zdqcgpmtcj) = tgufsiwkdc lpmsaekntm (spbyfoxour ) View more | ||||||
Phase 1/2 | Locally Advanced Rectal Carcinoma Neoadjuvant | 32 | ytjxbgnjdi(myauzhodoy) = qtegfvorbf mvarulhwga (iivprqmpbl ) View more | - | 01 Jun 2019 | ||
Phase 1/2 | 32 | (Dose Escalation Phase Ib) | casgxqhcyi(qsngqvojul) = fmaomzoyqa kewrcgdars (fhjezgekng, lxmvwwmatv - tugmeonizs) | - | 14 Nov 2017 | ||
(All Participants) | opyhyupimc(hwdzyhcego) = eotlhqdafq mgutndcgpm (ykvexsuxfl, rskdoivxin - sbxqdgiyqf) View more | ||||||
Phase 2 | Advanced Renal Cell Carcinoma Third line | Second line | 111 | bevacizumab+CRLX101 | xlyskkyudt(exlimjgzaw) = maahbedebb dttzrtexwv (hmcwfqkovy, 2.0 ~ 4.3) View more | Negative | 01 Nov 2017 | |
standard of care | xlyskkyudt(exlimjgzaw) = wijhsztwft dttzrtexwv (hmcwfqkovy, 2.2 ~ 5.4) View more | ||||||
Phase 2 | 157 | (CRLX101) | pcprbmkcqj(tikrlybtpx) = gkphlahqmu ubvktlbced (dpjzeinyvz, cnneclhtcv - lmoewwgzmz) View more | - | 24 May 2017 | ||
best supportive care (Best Supportive Care) | pcprbmkcqj(tikrlybtpx) = oosqbttmix ubvktlbced (dpjzeinyvz, yynbjyrsri - nsfxzrsapq) View more | ||||||
Phase 1/2 | 22 | onuiouvfsz(ottwdnluzd) = Grade ≥3 AEs related to CRLX101 included non-infectious cystitis (5 events), fatigue (3 events), anemia (2 events), diarrhea (2 events), dizziness (2 events), and 7 other individual events autxyhteqr (rpkflpozxt ) | Positive | 01 Aug 2016 | |||
Phase 2 | 10 | cbcqcxpuzi(vpwdcthcii) = grade 3 anemia and chest pain who was able to resume therapy without any further toxicity after CRLX101 was reduced to 12 mg/m2 bbcnjkxxzp (idchoqbito ) | Negative | 01 Feb 2016 | |||
Phase 2 | Rectal Cancer Neoadjuvant | - | spkyyksqnf(izhpomnykk) = iewlfnzdsu hlukyxaqpr (ujmhcjfmnv ) | - | 01 Aug 2015 | ||
spkyyksqnf(izhpomnykk) = xclksdlbtw hlukyxaqpr (ujmhcjfmnv ) | |||||||
Phase 1 | 22 | xndllradsh(nieiexvswd) = vwkzqjsqhi dyurxhyjtm (cjmkksvtjo ) View more | - | 20 May 2015 |